Home ›
Non-Muscle-Invasive Bladder Cancer Trials ›
NCT06319820
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Trial Details
NCT ID NCT06319820 Phase PHASE3
Sponsor Janssen Research & Development, LLC
Status RECRUITING
Cancer Type Non-Muscle-Invasive Bladder Cancer
Interventions Locations (sample) Little Rock, Arkansas, United States|34.74648,-92.28959 Los Alamitos, California, United States|33.80307,-118.07256 Los Angeles, California, United States|34.05223,-118.24368 Orange, California, United States|33.78779,-117.85311 San Diego, California, United States|32.71571,-117.16472
Key Eligibility Criteria
Main study only: Have a histologically confirmed diagnosis (within 90 days of randomization) of IR-NMIBC with at least one of the following criteri… Substudy only: Have a histologically confirmed new diagnosis (within 90 days of randomization) of IR-NMIBC for whom MMC is deemed the therapy of ch… Have a susceptible fibroblast growth factor receptor (FGFR) mutation or fusion either by urine testing or tumor tissue testing (from TURBT tissue),… Participants must be willing to undergo all study procedures (e.g., multiple cystoscopies from Screening through the end of study and TURBT for ass… For full eligibility, visit ClinicalTrials.gov .